VivoSeq
Oncology

Locally Advanced Basal Cell Carcinoma

3

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Locally Advanced Basal Cell Carcinoma is an early-stage landscape with 3 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

L19IL2

Philogen S.p.A.

L19TNF

Philogen S.p.A.

L19IL2/L19TNF

Philogen S.p.A.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 2 Controlled Randomized Study of the Efficacy of L19IL2 or L19TNF or L19IL2/L19TNF Intralesional Injections for the Treatment of Locally Advanced Basal Cell Carcinoma (LaBCC)
Recruiting·—·Phase 2·NCT07227350·180 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)